| Date Filed | Type | Description |
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results |
| 07/18/2023 |
4
| Fry Hannah (VP, Controller) has filed a Form 4 on Protara Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 10,075 shares
@ $2.56, valued at
$25.8k
|
|
| 07/05/2023 |
4
| Bandari Jathin (Chief Medical Officer) has filed a Form 4 on Protara Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 682 shares
@ $2.46, valued at
$1.7k
|
|
| 06/08/2023 |
4
| Smith Cynthia (Director) has filed a Form 4 on Protara Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $2.85, valued at
$28.5k
|
|
| 06/08/2023 |
4
| BESHAR LUKE M (Director) has filed a Form 4 on Protara Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $2.85, valued at
$28.5k
|
|
| 06/08/2023 |
4
| GARCEAU ROGER (Director) has filed a Form 4 on Protara Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $2.85, valued at
$28.5k
|
|
| 06/08/2023 |
4
| SARGEN GREGORY (Director) has filed a Form 4 on Protara Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $2.85, valued at
$28.5k
|
|
| 06/08/2023 |
4
| Levy Richard S (Director) has filed a Form 4 on Protara Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $2.85, valued at
$28.5k
|
|
| 06/08/2023 |
4
| Solomon Michael Edward (Director) has filed a Form 4 on Protara Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $2.85, valued at
$28.5k
|
|
| 06/08/2023 |
4
| Huang Jane (Director) has filed a Form 4 on Protara Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $2.85, valued at
$28.5k
|
|
| 06/08/2023 |
4
| Flannelly Barry P (Director) has filed a Form 4 on Protara Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $2.85, valued at
$28.5k
|
|
| 06/08/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 05/02/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/08/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/08/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/08/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 6% stake in Protara Therapeutics, Inc. |
| 02/10/2023 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
| 01/30/2023 |
4
| Fabbio Patrick (CFO) has filed a Form 4 on Protara Therapeutics, Inc.|
Txns:
| Granted 300,000 options to buy
@ $3.14, valued at
$942k
|
|
| 01/30/2023 |
3
| Fabbio Patrick (CFO) has filed a Form 3 on Protara Therapeutics, Inc. |
| 01/30/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/20/2023 |
4
| Fry Hannah (VP, Controller) has filed a Form 4 on Protara Therapeutics, Inc.|
Txns:
| Granted 5,900 shares
@ $0
Granted 35,400 options to buy
@ $3.02, valued at
$106.9k
|
|
| 01/20/2023 |
4
| Zummo Jacqueline (Chf Scientific Operations Off) has filed a Form 4 on Protara Therapeutics, Inc.|
Txns:
| Granted 19,900 shares
@ $0
Granted 119,300 options to buy
@ $3.02, valued at
$360.3k
|
|
| 01/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/11/2023 |
4
| Zummo Jacqueline (Chf Scientific Operations Off) has filed a Form 4 on Protara Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 5,225 shares
@ $3, valued at
$15.7k
|
|
|